Skip to main content
Signal8

CERO THERAPEUTICS HOLDINGS, INC. (CERO) Form 8-K — May 29, 2026

$CEROForm 8-KItems 1.01, 2.03, 3.02, 9.01Filed May 29, 2026, 4:05 PM ET0001213900-26-062802Original filing

Cero Therapeutics Holdings, Inc. issued a convertible promissory note to SRX Health Solutions, Inc. for a purchase price of $750,000, carrying a principal face value of $937,500 and bearing 10% annual interest. The note matures on May 28, 2027, and allows the lender to convert debt into common stock at a price equal to the lesser of $0.05 or 80% of the average of the five lowest intraday trading prices during the 20 days prior to conversion.

Key figures

Debt Amount
750000
Interest Rate
10
Maturity Date
2027-05-28
Conversion discount
80% of 5 lowest intraday prices over 20 days
Principal face value
937500
Conversion price floor
0.05
Beneficial ownership limit
4.99%

AI analysis

Red flags3 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.

    CERO THERAPEUTICS HOLDINGS, INC. (CERO) Form 8-K — May 29, 2026: AI Analysis | Signal8